Companies /Healthcare

Vertex Pharmaceuticals Inc

NASDAQ: VRTX Biotechnology
$548.04
â–² $0.75 (+0.14%) today
Markets open · 3:09pm ET

Q3 2025 Earnings

Reported Nov 3, 2025, 4:06pm ET · SEC source
$4.80
Beat +4.87%
EPS · est. $4.58
$3.1B
Beat +0.56%
Revenue · est. $3.1B
+6.5%
Beating market
VRTX vs S&P since report
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
−2%0+2%+4%Nov 3Nov 4report 4:06pm ETearnings−1.4%+1.9%
−2%0+2%+4%Nov 3Nov 4earnings−1.4%+1.9%
VRTX +1.9%S&P 500 −1.4%
−2%0+2%+4%Nov 3Nov 4report 4:06pm ETearnings−2.5%+1.9%
−2%0+2%+4%Nov 3Nov 4earnings−2.5%+1.9%
VRTX +1.9%NASDAQ −2.5%
−3%0+3%Nov 3Nov 11report 4:06pm ETearnings−0.0%+4.9%
−3%0+3%Nov 3Nov 11earnings−0.0%+4.9%
VRTX +4.9%S&P 500 −0.0%
−3%0+3%Nov 3Nov 11report 4:06pm ETearnings−1.6%+4.9%
−3%0+3%Nov 3Nov 11earnings−1.6%+4.9%
VRTX +4.9%NASDAQ −1.6%
−1.02%
Day of report
−1.11%
Next session
+1.79%
One week
+8.02%
30 days

S&P 500 over the same 30 days: +1.55%.

Did VRTX Beat Earnings? Q3 2025 Results

Vertex Pharmaceuticals delivered a solid beat on both the top and bottom lines in Q3 2025, with non-GAAP EPS of $4.80 clearing the $4.58 consensus by 4.87% and revenue of $3.08 billion edging past estimates by 0.56%, representing 11% growth year over year. The quarter's strength was anchored by the company's dominant cystic fibrosis franchise, with TRIKAFTA/KAFTRIO contributing $2.65 billion alone, while newer launches added meaningful momentum: ALYFTREK generated $247 million in its first year on market, JOURNAVX added $19.60 million following its March debut, and CASGEVY contributed $16.90 million as cell therapy uptake continues to build. Despite the headline beat, <a href="https://247wallst.com/investing/2025/11/03/vertex-falls-10-after-reporting-mixed-q3-results/">shares came under pressure</a> as investors weighed the pace of pipeline diversification. Looking ahead, Vertex narrowed its full-year 2025 revenue guidance to $11.90 billion to $12.00 billion and lowered its non-GAAP effective tax rate outlook to 17%-18%, while signaling increased investment in its povetacicept kidney disease program and JOURNAVX commercial expansion.

Key Takeaways
  • Continued strong CF patient demand including ALYFTREK uptake
  • Favorable net pricing in CF versus prior year in the U.S.
  • Early contributions from CASGEVY and JOURNAVX launches
  • Solid international performance across multiple geographies

“Vertex delivered strong results across the board in the third quarter, extending our leadership in CF, continuing to build global momentum for CASGEVY, and advancing the launch of JOURNAVX in acute pain.”

Vertex Pharmaceuticals CEO, on the earnings call

Forward Guidance & Outlook

Vertex refined full year 2025 guidance with total revenue now expected to be $11.9 to $12.0 billion (narrowed from $11.85 to $12.0 billion), assuming continued CF growth including global ALYFTREK launch, continued CASGEVY uptake, and early JOURNAVX contributions. Combined non-GAAP R&D, AIPR&D, and SG&A expenses now expected to be $5.0 to $5.1 billion (increased from $4.9 to $5.0 billion), reflecting acceleration of povetacicept programs and increased JOURNAVX commercial investment. Non-GAAP effective tax rate guidance was lowered to 17% to 18% from 20.5% to 21.5%, incorporating one-time tax benefits including Alpine-related R&D tax credits and anticipated recognition of deferred tax benefits. Tariff cost impact expected to be immaterial in 2025.

VRTX YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$900.0M$1.8B$2.7B$2.8B$3.1BRevenue$2.4B$2.7BGross Profit$1.1B$1.2BOperating Income$1.0B$1.1BNet Income
$0$900.0M$1.8B$2.7BRevenueGross ProfitOperating IncomeNet Income

VRTX Revenue by Segment

TRIKAFTA/KAFTRIO$2.7B
ALYFTREK$247.0M
Other product revenues$175.8M
CASGEVY
JOURNAVX

VRTX Revenue by Geography

United States$2.0B+15.0%
Rest of World$1.1B+4.0%

Figures from SEC filings and company reports. Not investment advice.